ABOUT INDEXING BOARD ARCHIVES AUTHOR GUIDELINES SUBMIT PAPER AUTHOR'S PAGE NEWS, EVENTS CONTACT
REVISTA DE CHIMIE
Cite as: Rev. Chim.
https://doi.org/10.37358/Rev.Chim.1949

OSIM Nr. R102355
ISSN Online 2668-8212
ISSN Print: 1582-9049
ISSN-L: 1582-9049

REVISTA DE CHIMIE Latest Issue

LATEST ISSUE >>>

   Volume 75, 2024
   Volume 74, 2023
   Volume 73, 2022
   Volume 72, 2021
   Volume 71, 2020
   Volume 70, 2019
   Volume 69, 2018
   Volume 68, 2017
   Volume 67, 2016
   Volume 66, 2015
   Volume 65, 2014
   Volume 64, 2013
   Volume 63, 2012
   Volume 62, 2011
   Volume 61, 2010
   Volume 60, 2009
   Volume 59, 2008
   Volume 58, 2007
 
<<<< back

Revista de Chimie (Rev. Chim.), Year 2019, Volume 70, Issue 3, 1017-1022

https://doi.org/10.37358/RC.19.3.7053

Ema-Cristina Borsi, Adina Bucur, Cristina Potre Oncu, Ovidiu Potre Oncu, Bianca Cerbu, Dan Costachescu, Ioana Ionita, Constantin Tudor Luca, Hortensia Ionita

First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone

Abstract:

Multiple myeloma (MM) is typically sensitive to a range of cytotoxic agents, both as initial therapy and as relapsed disease treatment. Unfortunately, the responses are transient, and MM is not considered curable with the current approaches. This paper aims to assess the response to first line treatment of patients included in the study and their correlation with the negative prognostic factors in multiple myeloma: age over 60 years, male gender, anemia, hypercalcemia, elevated levels of creatinine, Beta 2 microglobulin, hypoalbuminemia and Bence-Jones proteins type. The study was conducted on a group of 105 patients admitted to the Hematology Department of the Municipal Emergency Clinical Hospital of Timisoara from 01 January 2013 until 31 December 2017. Twenty-seven patients received VAD regimen, while 78 underwent Bortezomib + Dexamethasone regimen as fist line therapy. When analyzing anthropometrical data, different gender distribution in the two groups of patients is seen, while a higher percentage of patients over 60 years is observed in both groups, with 77.7% in the VAD group (21 out of 27 patients) and 56.4% in the group treated with Bortezomib + Dexamethasone (44 out of 78 patients). Only some of the factors analyzed in our study statistically significantly influenced the response to treatment and the duration of survival, i.e.: age over 60 years, hemoglobin [10g/dL, platelets under 150000/mm3, creatinine ]2mg/dL, serum calcium ]10mg / dL, increased C-reactive protein, low serum albumin levels, high levels of Beta 2 microglobulin, total serum protein, as well as presence of cells in the peripheral smear. Defining a panel of negative prognostic factors that influence the evolution and response to multiple myeloma treatment would allow for tailoring of personalized therapies for each patient.
Keywords:
treatment; multiple myeloma; survival

Issue: 2019, Volume 70, Issue 3
Pages: 1017-1022
Publication date: 2019/4/15
https://doi.org/10.37358/RC.19.3.7053
download pdf   Download Pdf Article
Creative Commons License
This article is published under the Creative Commons Attribution 4.0 International License
Citation Styles
Cite this article as:
BORSI, E., BUCUR, A., ONCU, C.P., ONCU, O.P., CERBU, B., COSTACHESCU, D., IONITA, I., LUCA, C.T., IONITA, H., First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone, Rev. Chim., 70(3), 2019, 1017-1022.

Vancouver
Borsi E, Bucur A, Oncu CP, Oncu OP, Cerbu B, Costachescu D, Ionita I, Luca CT, Ionita H. First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone. Rev. Chim.[internet]. 2019 Mar;70(3):1017-1022. Available from: https://doi.org/10.37358/RC.19.3.7053


APA 6th edition
Borsi, E., Bucur, A., Oncu, C.P., Oncu, O.P., Cerbu, B., Costachescu, D.,... Ionita, H. (2019). First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone. Revista de Chimie, 70(3), 1017-1022. https://doi.org/10.37358/RC.19.3.7053


Harvard
Borsi, E., Bucur, A., Oncu, C.P., Oncu, O.P., Cerbu, B., Costachescu, D., Ionita, I., Luca, C.T., Ionita, H. (2019). 'First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone', Revista de Chimie, 70(3), pp. 1017-1022. https://doi.org/10.37358/RC.19.3.7053


IEEE
E. Borsi, A. Bucur, C.P. Oncu, O.P. Oncu, B. Cerbu, D. Costachescu, I. Ionita, C.T. Luca, H. Ionita, "First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone". Revista de Chimie, vol. 70, no. 3, pp. 1017-1022, 2019. [online]. https://doi.org/10.37358/RC.19.3.7053


Text
Ema-Cristina Borsi, Adina Bucur, Cristina Potre Oncu, Ovidiu Potre Oncu, Bianca Cerbu, Dan Costachescu, Ioana Ionita, Constantin Tudor Luca, Hortensia Ionita,
First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone,
Revista de Chimie,
Volume 70, Issue 3,
2019,
Pages 1017-1022,
ISSN 2668-8212,
https://doi.org/10.37358/RC.19.3.7053.
(https://revistadechimie.ro/Articles.asp?ID=7053)
Keywords: treatment; multiple myeloma; survival


RIS
TY - JOUR
T1 - First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone
A1 - Borsi, Ema-Cristina
A2 - Bucur, Adina
A3 - Oncu, Cristina Potre
A4 - Oncu, Ovidiu Potre
A5 - Cerbu, Bianca
A6 - Costachescu, Dan
A7 - Ionita, Ioana
A8 - Luca, Constantin Tudor
A9 - Ionita, Hortensia
JF - Revista de Chimie
JO - Rev. Chim.
PB - Revista de Chimie SRL
SN - 2668-8212
Y1 - 2019
VL - 70
IS - 3
SP - 1017
EP - 1022
UR - https://doi.org/10.37358/RC.19.3.7053
KW - treatment
KW - multiple myeloma
KW - survival
ER -


BibTex
@article{RevCh2019P1017,
author = {Borsi Ema-Cristina and Bucur Adina and Oncu Cristina Potre and Oncu Ovidiu Potre and Cerbu Bianca and Costachescu Dan and Ionita Ioana and Luca Constantin Tudor and Ionita Hortensia},
title = {First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone},
journal = {Revista de Chimie},
volume = {70},
number = {3},
pages = {1017-1022},
year = {2019},
issn = {2668-8212},
doi = {https://doi.org/10.37358/RC.19.3.7053},
url = {https://revistadechimie.ro/Articles.asp?ID=7053}
}
 
<<<< back
 
PUBLISHING SECTION
Author Guidelines
 * Paper Drafting
 * Paper Template
 * Ethical Statement
 * Paper Submission
Ghidul Autorului (ro)
Submit Paper
Author's Page
Publishing Ethics
Peer Review Process
Open Access & Archiving Policy
 Search Authors
 LATEST NEWS
REvista de Chimie NUMAR OMAGIAL PETRU PONI.. detalii
REvista de Chimie Revista de Chimie - 70 de ani de aparitie neintrerupta.. detalii
dictionar English-Romanian Dictionary for Mechanical Engineering
(download pdf)
  News, Events
Crossref Member Badge
 DOI  logo
 Gold Open Access | Source=http://www.plos.org/  | Author=art designer at PLoS
Creative Commons License
 Conferences of Contemporary
 Chemistry
 Biblioteca Chimiei
 Materiale Plastice